AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Pre-mRNA-processing factor 6 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Pre-mRNA-processing factor 6 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Pre-mRNA-processing factor 6, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Pre-mRNA-processing factor 6. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Pre-mRNA-processing factor 6. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Pre-mRNA-processing factor 6 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Pre-mRNA-processing factor 6
partner:
Reaxense
upacc:
O94906
UPID:
PRP6_HUMAN
Alternative names:
Androgen receptor N-terminal domain-transactivating protein 1; PRP6 homolog; U5 snRNP-associated 102 kDa protein
Alternative UPACC:
O94906; B2RAR5; B3KMC6; O95109; Q5VXS5; Q9H3Z1; Q9H4T9; Q9H4U8; Q9NTE6
Background:
Pre-mRNA-processing factor 6, also known as Androgen receptor N-terminal domain-transactivating protein 1, plays a crucial role in pre-mRNA splicing as part of the U4/U6-U5 tri-snRNP complex. This protein is essential for the assembly of the spliceosome, a complex responsible for removing introns from pre-mRNA. It also modulates the transactivation activity of AR and NR3C1, highlighting its significance in gene expression regulation.
Therapeutic significance:
Pre-mRNA-processing factor 6 is linked to Retinitis pigmentosa 60, a retinal dystrophy characterized by loss of vision and pigment deposits in the retina. Understanding the role of Pre-mRNA-processing factor 6 could open doors to potential therapeutic strategies for this debilitating condition.
